Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101’s initial efficacy and safety profile and broad ...

JANESVILLE, WI, USA I 18, 2024 I GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...

PHILADELPHIA, PA, USA I 18, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older ...

NanoVation will receive research funding and is eligible to receive up to approximately US$600 million in up-front cash and potential milestone payments, as well as tiered royalties on future product ...

– Initiation of the second component of the Phase 1 study, in adult DMD patients, expected in Q1 2025 ...

EAST HANOVER, NJ, USA I 17, 2024 I Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in ...

DANVILLE, CA, USA I September 17, 2024 I Nexilico, a pioneer in precision microbiome engineering, and Siolta Therapeutics, a leader in the development of live ...

SOUTH SAN FRANCISCO, CA, USA I September 17, 2024 I Nura Bio Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of ...

BARCELONA, Spain I 17, 2024 I Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in ...

Late-breaking oral presentation will discuss the potential of ZL-1503 as a novel treatment for moderate-to-severe atopic dermatitis and other diseases ...

HDT bio’s Rapid-Response Roadmap for RNA vaccines (R 4) project granted a five-year subaward for $2M per year SEATTLE, WA, USA I 17, 2024 I HDT Bio Corp., a clinical-stage biopharmaceutical company ...